Le Lézard
Classified in: Health
Subject: SVY

LANAP Protocol is Helping to Reduce Opioid Addiction


CERRITOS, Calif., Feb. 14, 2018 /PRNewswire/ -- As featured in Shape magazine, the LANAP protocol is helping to reduce dental patient dependency on opioids. 99.5% of LANAP clinicians have stopped writing prescriptions for opioids post-LANAP surgery and instead prescribe over-the-counter pain relief.

Millennium Dental Technologies, Inc. manufacturer of the PerioLase MVP-7 for the LANAP protocol gum disease treatment, FDA cleared for True Regeneration

"LANAP surgery has tremendous benefits for patients," comments Robert H. Gregg II, DDS, president of Millennium Dental Technologies and the inventor of the LANAP® protocol. "The PerioLase MVP-7 was specifically designed with the ideal parameters to effectively treat gum disease following the strict LANAP protocol. The laser energy destroys bacteria and endotoxins; stimulating the body's natural healing response during the process.  By removing scalpels and sutures, we remove the patient's fear and increase treatment acceptance."

Studies show 99% of oral surgeons prescribe opioids for wisdom teeth extraction, yet 54% of opioids prescribed are not used.  Estimates for opioid prescription are similar for periodontal flap surgery using scalpels and sutures.  The LANAP protocol replaces traditional osseous surgery and is the only laser periodontal surgery with scientific evidence supporting the FDA clearance of True Periodontal Regeneration

"Not only can LANAP treatment regenerate the bone and tissues lost to periodontal disease with virtually no pain, the LAPIP treatment is saving dental implants," continues Dr Gregg. "We are combating two of dentistry's biggest challenges ? saving ailing and failing implants while achieving the gold standard in Periodontics, that of True Periodontal Regeneration."

The LANAP protocol is the only laser periodontal protocol validated with two human histological studies and supported with a 6 month money-back clinical results guarantee. LANAP regenerative specialists are required to complete intensive training through the Institute for Advanced Laser Dentistry, including treating three live patients over the course of 12 months.

ABOUT MILLENNIUM DENTAL TECHNOLOGIES, INC.:  Millennium Dental Technologies, Inc., is the developer of the LANAP protocol for the treatment of gum disease, the LAPIP protocol for ailing dental implants, and the manufacturer of the PerioLase MVP-7 dental laser. By providing a simple and comfortable experience with unique bone-building clinical results, MDT's FDA-cleared LANAP protocol removes the fear from gum disease treatment, offering a vastly less painful and less invasive regenerative treatment alternative to conventional surgery. The company's founding clinician, Robert H. Gregg II, continues to operate the company with the vision: To create better clinical outcomes in periodontal disease patients?remaining true to the guiding principle?"It's all about the patient." 

 

SOURCE Millennium Dental Technologies, Inc.


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: